Literature DB >> 19937426

Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study.

S D Berry1, D P Kiel, M G Donaldson, S R Cummings, J A Kanis, H Johansson, E J Samelson.   

Abstract

UNLABELLED: We applied the 2008 National Osteoporosis Foundation (NOF) Guidelines to Framingham Osteoporosis Study participants and found nearly one half of Caucasian postmenopausal women and one sixth of men aged 50 years and older would be recommended for osteoporosis treatment. Given the high proportion of persons recommended for treatment, NOF Guidelines may need to be re-evaluated with respect to budget impact.
INTRODUCTION: Little is known about the public health impact of the NOF Guidelines. Therefore, we determined the proportion of US Caucasians recommended for treatment of osteoporosis according to NOF Guidelines (2003 and 2008).
METHODS: One thousand nine hundred and forty-six postmenopausal women and 1,681 men aged > or =50 years from the Framingham Study with information on bone mineral density (1987-2001) were included. Information on clinical predictors was used to estimate the 10-year probability of hip and major osteoporotic fracture by FRAX (version 3.0).
RESULTS: Overall proportion of women meeting treatment criterion was less when the 2008 NOF Guidelines were applied (41.1%) compared with 2003 Guidelines (47.8%). The proportion of women aged <65 years meeting treatment criterion was much less when applying 2008 Guidelines (23.1% in 2003, 8.3% in 2008), whereas the proportion of women aged >75 years increased slightly (78.3% in 2003, 86.0% in 2008). Seventeen percent of men aged > or =50 years met treatment criterion (2.5% aged 50-64 years, 49.8% aged >75 years).
CONCLUSIONS: Nearly one half of Caucasian postmenopausal women and one sixth of men aged 50 years and older would be recommended for osteoporosis treatment according to 2008 NOF Guidelines. Given the high proportion of persons recommended for treatment, NOF Guidelines may need to be re-evaluated with respect to budget impact.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19937426      PMCID: PMC2889692          DOI: 10.1007/s00198-009-1127-3

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  27 in total

1.  Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians.

Authors:  Amir Qaseem; Vincenza Snow; Paul Shekelle; Robert Hopkins; Mary Ann Forciea; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-05-06       Impact factor: 25.391

2.  Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

Authors:  Russel Burge; Bess Dawson-Hughes; Daniel H Solomon; John B Wong; Alison King; Anna Tosteson
Journal:  J Bone Miner Res       Date:  2007-03       Impact factor: 6.741

3.  Effect of birth cohort on risk of hip fracture: age-specific incidence rates in the Framingham Study.

Authors:  Elizabeth J Samelson; Yuqing Zhang; Douglas P Kiel; Marian T Hannan; David T Felson
Journal:  Am J Public Health       Date:  2002-05       Impact factor: 9.308

4.  Incidence and risk factors for vertebral fracture in women and men: 25-year follow-up results from the population-based Framingham study.

Authors:  Elizabeth J Samelson; Marian T Hannan; Yuqing Zhang; Harry K Genant; David T Felson; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2006-08       Impact factor: 6.741

5.  FRAX and the assessment of fracture probability in men and women from the UK.

Authors:  J A Kanis; O Johnell; A Oden; H Johansson; E McCloskey
Journal:  Osteoporos Int       Date:  2008-02-22       Impact factor: 4.507

6.  Secular trends in alcohol consumption over 50 years: the Framingham Study.

Authors:  Yuqing Zhang; Xinxin Guo; Richard Saitz; Daniel Levy; Emily Sartini; Jingbo Niu; R Curtis Ellison
Journal:  Am J Med       Date:  2008-08       Impact factor: 4.965

7.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

8.  The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.

Authors:  B Dawson-Hughes; A C Looker; A N A Tosteson; H Johansson; J A Kanis; L J Melton
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

9.  Vertebral fracture assessment (VFA) with a densitometer predicts future fractures in elderly women unselected for osteoporosis.

Authors:  Eugene V McCloskey; Sreekanth Vasireddy; Jane Threlkeld; Joanne Eastaugh; Ailsa Parry; Nicolas Bonnet; Monique Beneton; John A Kanis; Diane Charlesworth
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

10.  Updated fracture incidence rates for the US version of FRAX.

Authors:  B Ettinger; D M Black; B Dawson-Hughes; A R Pressman; L J Melton
Journal:  Osteoporos Int       Date:  2009-08-25       Impact factor: 4.507

View more
  22 in total

1.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids.

Authors:  J A Kanis; H Johansson; A Oden; E V McCloskey
Journal:  Osteoporos Int       Date:  2011-01-13       Impact factor: 4.507

2.  Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) Study.

Authors:  Bruce Ettinger; Hau Liu; Terri Blackwell; Andrew R Hoffman; Kristine E Ensrud; Eric S Orwoll
Journal:  J Clin Densitom       Date:  2012-03-21       Impact factor: 2.617

3.  Metabolism-guided design of short-acting calcium-sensing receptor antagonists.

Authors:  James A Southers; Jonathan N Bauman; David A Price; Paul S Humphries; Gayatri Balan; John F Sagal; Tristan S Maurer; Yan Zhang; Robert Oliver; Michael Herr; David R Healy; Mei Li; Brendon Kapinos; Gwendolyn D Fate; Keith A Riccardi; Vishwas M Paralkar; Thomas A Brown; Amit S Kalgutkar
Journal:  ACS Med Chem Lett       Date:  2010-05-13       Impact factor: 4.345

Review 4.  BMD screening in older women: initial measurement and testing interval.

Authors:  Margaret L Gourlay; John S Preisser; Li-Yung Lui; Jane A Cauley; Kristine E Ensrud
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

5.  Changes in bone mineral density may predict the risk of fracture differently in older adults according to fall history.

Authors:  Sarah D Berry; Robert R McLean; Marian T Hannan; L Adrienne Cupples; Douglas P Kiel
Journal:  J Am Geriatr Soc       Date:  2014-11-29       Impact factor: 5.562

6.  The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008.

Authors:  B Dawson-Hughes; A C Looker; A N A Tosteson; H Johansson; J A Kanis; L J Melton
Journal:  Osteoporos Int       Date:  2011-06-30       Impact factor: 4.507

7.  Fracture risk assessment without bone density measurement in routine clinical practice.

Authors:  W D Leslie; S Morin; L M Lix; H Johansson; A Oden; E McCloskey; J A Kanis
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

8.  Pharmacokinetics and osteogenic potential of PEGylated NELL-1 in vivo after systemic administration.

Authors:  Jin Hee Kwak; Yulong Zhang; Juyoung Park; Eric Chen; Jia Shen; Chirag Chawan; Justine Tanjaya; Soonchul Lee; Xinli Zhang; Benjamin M Wu; Kang Ting; Chia Soo
Journal:  Biomaterials       Date:  2015-04-24       Impact factor: 12.479

Review 9.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

10.  Use of pharmacologic agents for the primary prevention of osteoporosis among older women with low bone mass.

Authors:  J Zhang; E Delzell; J R Curtis; F Hooven; S H Gehlbach; F A Anderson; K G Saag
Journal:  Osteoporos Int       Date:  2013-08-28       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.